Mary L. (Nora) Disis

Director, UW Medicine Cancer Vaccine Institute. Editor in Chief, JAMA Oncology. Research: vaccines for the prevention of cancer and cancer relapse.

[Mary L. (Nora) Disis @DrNDisis]

https://t.co/qMJjuFjpAe

[UW Cancer Vaccine Institute @UWCancerVaccine]

CVI Director @DrNDisis, Exec Dir @kirandhillonphd & colleagues are at #SITC2022! Grad students & postdocs interested in an exciting career in cancer vaccines & tumor immunology, we want to meet you! Discovery, translation, and clinical trials under one roof. Email: [email protected]

[Mary L. (Nora) Disis @DrNDisis]

@UWCancerVaccine Link to the paper in JITC: https://t.co/Avvy00Nnvz
@jitcancer @sitcancer @UWCancerVaccine @UWMedicine

[Mary L. (Nora) Disis @DrNDisis]

@UWCancerVaccine Recurrent disease, platinum refractory. Result: 10%PR, 52% SD. But 43% PD-L1+ tumors had PR! In correlative studies-peripheral blood CD8+PD1+Ki67+/tumor burden ratio predicted survival. Interesting results and well written paper John!

[UW Cancer Vaccine Institute @UWCancerVaccine]

We’re excited to share a new paper by CVI’s Dr. John Liao on a clinical trial for combination Pembrolizumab and low dose carboplatin in women with recurrent, platinum resistant ovarian cancer. Read more https://t.co/4T1amd0mtv

#ovariancancerawarenessmonth #gyncsm #immunotherapy

[Science in Seattle @science_seattle]

👨‍⚕️👩‍⚕️ Drs. Sasha Stanton (@sestant29), Nora Disis (@DrNDisis), and fellow @UWCancerVaccine researchers found that candidate targets recovered from mouse #mammary tumor models are also immunogenic in human #BreastCancer.

📚 Abstact: https://t.co/udZvm0sfIb

[UW Medicine Newsroom @uwmnewsroom]

5 immune response markers might predict #COVID19 patient outcomes & possibly become useful in candidate vaccine assessment, according to @ImmunityCP @CellCellPress study @ragoninstitute & @UWMedicine headed by Galit Alter & Helen Chu https://t.co/2cnwu1MirL

[H. Jack West, MD, FASCO @JackWestMD]

In the wake of #ADAURA trial, what will your practice be for molecular testing in patients with resected stage IB-IIIA NSCLC?

Please amplify as needed in the comments.

#LCSM

[Ying.Liu.0131 @0131Liu]

Thanks for my nicest colleagues! I am the best, because all of you! @UWCancerVaccine

[Mary L. (Nora) Disis @DrNDisis]

Laura is an amazing scientist!

[UW Cancer Vaccine Institute @UWCancerVaccine]

CVI’s Dr. Laura Riolobos is making a #vaccine for #liposarcoma, to help her friend & others with this rare #cancer. Read more: https://t.co/QQv9f3U6vu @UWMedicine #SarcomaAwareness #CureSarcoma #Sarcoma #Research

[Mary L. (Nora) Disis @DrNDisis]

Pembrolizumab After Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer https://t.co/9AqQsD6lmj New at @JAMA Onc-ablation of oligometastatic NSCLC followed by immune checkpoint: OS at 12 mo-90%. Novel and promising application of immune checkpoint inhibition.

[Mary L. (Nora) Disis @DrNDisis]

Regulatory roles of IL-10–producing human follicular T cells https://t.co/k5EP4F364j

[Mary L. (Nora) Disis @DrNDisis]

I'm a fan of testing early. Immune therapy more be more effective with less bulky disease.

[Tom Jayram @TomJayram]

Fascinating. Test early or late in the disease course? Seems like later could pick up more candidates for IO

[Arjun Gupta @guptaarjun90]

Patient page on #CIPN (Chemo Induced Peripheral Neuropathy), in @JAMAOnc w/ @TimothyJBrownMD @ramsedhom
#QOL matters. Can be photocopied non-commercially to share with patients.
https://t.co/pJL1hjuPDy

[Mary L. (Nora) Disis @DrNDisis]

Thank you UW CVI #ImmunoOnc19 @UWCancerVaccine

[Ravi A Madan M.D. @Dr_RaviMadan]

Just a reminder that you can’t top @thenci ‘s @gulleyj1 for #immunotherapy on Twitter 😉. Thank you also @DrChoueiri @DrNDisis @asco @sitc @PGrivasMDPhD @xiaoweimd @CMAnnunziata @phase1oncomd et al for a great #ImmunoOnc19.

[Mary L. (Nora) Disis @DrNDisis]

VERY IMPORTANT COMMENT!!! #ImmunoOnc19 @UWCancerVaccine

[A.n.n. @fireflyann]

if presenters include NCT trial number
1) attendees can look at some of the perameters of trial (e.g. dosing)
2) clinicians can find out that this presentation of findings exist
3) if there is a related trial (or an open arm), patients can find out more about trial.
#ImmunoOnc19

[Mary L. (Nora) Disis @DrNDisis]

Dr. Kandalaft points out that there are many types of antigens that can be used for vaccination, neo antigens of all types- not just point mutations. Target epigenetic changes, phospho Ag...etc. #ImmunoOnc19 @UWCancerVaccine

[Mary L. (Nora) Disis @DrNDisis]

Dr. Palucka highlights the importance of DC in mediating response to ICI. Recent Immunity paper implicated IFN-g and IL-12 in T cell DC cross-talk. https://t.co/GMz0gUVuF4 #ImmunoOnc19 @UWCancerVaccine

[Mary L. (Nora) Disis @DrNDisis]

Dendritic cells are the most important antigen presenting cells for stimulating T-cell responses to cancer. Nobel Prize winning tumor immunologist Dr. Ralph Steinman was honored for his work in this area. #ImmunoOnc19

[Mary L. (Nora) Disis @DrNDisis]

Dr. Palucka highlights the issues associated with mutated antigen vaccines; the mutations have to be presented enodogenously in the patients MHC. Most are not. #Immunotherapy #immunoonc19 @UWCancerVaccine

[Mary L. (Nora) Disis @DrNDisis]

@DrBetofMDPhD @DrChoueiri @DrRoyHerbstYale Key question on risk. Would depend on what we now know about the AE, the patient population, etc. The original AE with ICI begged that question A LOT- now we know how to treat effectively and catch early #ImmunoOnc19